$XLO
Xilio Therapeutics Inc

2021 Q4 Form 10-Q Financial Statement

#000155837021016476 Filed on December 02, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.204M $5.491M $2.928M
YoY Change 180.19% 73.77%
% of Gross Profit
Research & Development $11.35M $10.47M $17.67M
YoY Change -35.76% -8.64%
% of Gross Profit
Depreciation & Amortization $394.0K $382.0K $657.0K
YoY Change -40.03% 23.23%
% of Gross Profit
Operating Expenses $19.56M $15.96M $20.60M
YoY Change -5.04% 9.15%
Operating Profit -$15.96M
YoY Change 9.15%
Interest Expense -$100.0K -$200.0K
YoY Change -50.0%
% of Operating Profit
Other Income/Expense, Net -$45.00K -$290.0K $23.00K
YoY Change -295.65% 47.96%
Pretax Income -$19.70M -$16.25M -$20.77M
YoY Change -5.16% 9.66%
Income Tax
% Of Pretax Income
Net Earnings -$19.70M -$16.25M -$20.77M
YoY Change -5.16% 9.66%
Net Earnings / Revenue
Basic Earnings Per Share -$21.27
Diluted Earnings Per Share -$738.8K -$21.27 -$779.0K
COMMON SHARES
Basic Shares Outstanding 27.47M 763.9K
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $198.1M $99.77M
YoY Change
Cash & Equivalents $198.1M $99.77M $19.24M
Short-Term Investments
Other Short-Term Assets $4.464M $3.397M $44.00K
YoY Change 10045.45%
Inventory
Prepaid Expenses $2.408M $1.308M
Receivables
Other Receivables
Total Short-Term Assets $202.5M $105.6M $20.59M
YoY Change 883.57%
LONG-TERM ASSETS
Property, Plant & Equipment $7.620M $7.108M $7.367M
YoY Change 3.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $393.0K $427.0K $500.0K
YoY Change -21.4%
Total Long-Term Assets $15.54M $15.15M $15.73M
YoY Change -1.17%
TOTAL ASSETS
Total Short-Term Assets $202.5M $105.6M $20.59M
Total Long-Term Assets $15.54M $15.15M $15.73M
Total Assets $218.1M $120.7M $36.32M
YoY Change 500.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.144M $3.822M $5.444M
YoY Change -42.25%
Accrued Expenses $8.751M $8.194M $13.73M
YoY Change -36.27%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $12.78M $12.87M $22.16M
YoY Change -42.32%
LONG-TERM LIABILITIES
Long-Term Debt $9.628M $9.580M
YoY Change
Other Long-Term Liabilities $118.0K $1.525M $1.127M
YoY Change -89.53%
Total Long-Term Liabilities $118.0K $1.525M $1.127M
YoY Change -89.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.78M $12.87M $22.16M
Total Long-Term Liabilities $118.0K $1.525M $1.127M
Total Liabilities $32.63M $34.29M $41.60M
YoY Change -21.56%
SHAREHOLDERS EQUITY
Retained Earnings -$160.9M -$141.2M -$85.09M
YoY Change 89.09%
Common Stock $3.000K $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.4M -$136.5M -$83.29M
YoY Change
Total Liabilities & Shareholders Equity $218.1M $120.7M $36.32M
YoY Change 500.44%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$19.70M -$16.25M -$20.77M
YoY Change -5.16% 9.66%
Depreciation, Depletion And Amortization $394.0K $382.0K $657.0K
YoY Change -40.03% 23.23%
Cash From Operating Activities -$17.16M -$20.72M -$23.17M
YoY Change -25.92% 98.08%
INVESTING ACTIVITIES
Capital Expenditures -$378.0K -$114.0K -$682.0K
YoY Change -44.57% -120.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$378.0K -$114.0K -$682.0K
YoY Change -44.57% -80.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.8M 301.0K 60.00K
YoY Change 192943.33% -530.0%
NET CHANGE
Cash From Operating Activities -17.16M -20.72M -23.17M
Cash From Investing Activities -378.0K -114.0K -682.0K
Cash From Financing Activities 115.8M 301.0K 60.00K
Net Change In Cash 98.29M -20.53M -23.79M
YoY Change -513.17% 84.97%
FREE CASH FLOW
Cash From Operating Activities -$17.16M -$20.72M -$23.17M
Capital Expenditures -$378.0K -$114.0K -$682.0K
Free Cash Flow -$16.78M -$20.61M -$22.48M
YoY Change -25.35% 86.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
763869
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
612657
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99800000
us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
dei Entity Central Index Key
EntityCentralIndexKey
0001840233
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
427000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39836000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26243000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5491000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7725000
xlo Deferred Offering Costs Included In Accounts Payable Or Accrued Expenses
DeferredOfferingCostsIncludedInAccountsPayableOrAccruedExpenses
879000
xlo Derivative Liability Recognized
DerivativeLiabilityRecognized
250000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-56099000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34447000
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-21.27
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-24.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-76.18
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
736416
CY2021Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
478283
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
66788528
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14819000
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
174783481
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
66788528
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16251000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-72.02
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40925
dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
430-4680
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
XLO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27468948
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99767000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19238000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2408000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1308000
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3397000
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
44000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
105572000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
20590000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1551000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7108000
CY2021Q3 us-gaap Assets
Assets
120725000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7367000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6065000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
7412000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6309000
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
9580000
CY2020Q4 us-gaap Assets
Assets
36317000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3822000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5444000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8194000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13732000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
773000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
564000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2333000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12871000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22155000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10316000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10908000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1525000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1127000
CY2021Q3 us-gaap Liabilities
Liabilities
34292000
CY2020Q4 us-gaap Liabilities
Liabilities
41602000
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
174808481
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
174783481
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
133602056
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
66788528
CY2021Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
225500000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
80250000
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
222888000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
78002000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220400000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
914760
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
778949
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
126000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
973898
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
689929
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4730000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1799000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-141185000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85086000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-136455000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120725000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36317000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10470000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11460000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15961000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3163000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15652000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
14623000
us-gaap Operating Expenses
OperatingExpenses
55488000
us-gaap Operating Expenses
OperatingExpenses
33968000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15961000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14623000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55488000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33968000
CY2021Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
290000
CY2020Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
196000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
611000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
479000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-290000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-196000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-611000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-479000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16251000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14819000
us-gaap Net Income Loss
NetIncomeLoss
-56099000
us-gaap Net Income Loss
NetIncomeLoss
-34447000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21.27
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-24.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-76.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-72.02
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
763869
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
612657
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
736416
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
478283
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
794000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16668000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-99137000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1002000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23180000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-121309000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1091000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-16251000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-136455000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-29523000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
96000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8118000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-37545000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
151000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11510000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-48904000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2802000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
683000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-14819000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-63034000
us-gaap Profit Loss
ProfitLoss
-56099000
us-gaap Profit Loss
ProfitLoss
-34447000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1105000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
724000
xlo Noncash Interest Expense
NoncashInterestExpense
121000
xlo Noncash Interest Expense
NoncashInterestExpense
-2000
us-gaap Share Based Compensation
ShareBasedCompensation
2887000
us-gaap Share Based Compensation
ShareBasedCompensation
930000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-19000
xlo Fair Value Adjustments Of Warrants And Derivative Liabilities
FairValueAdjustmentsOfWarrantsAndDerivativeLiabilities
199000
xlo Fair Value Adjustments Of Warrants And Derivative Liabilities
FairValueAdjustmentsOfWarrantsAndDerivativeLiabilities
431000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3597000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-244000
xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-224000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1626000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
338000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6459000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5743000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-383000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-129000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63589000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23386000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
722000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2080000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-722000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2080000
us-gaap Repayments Of Debt
RepaymentsOfDebt
1000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
975000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
63000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
71000
xlo Proceeds From Issuance Of Preferred Units
ProceedsFromIssuanceOfPreferredUnits
9969000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144842000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9904000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
80531000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15562000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49039000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101320000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33477000
us-gaap Interest Paid Net
InterestPaidNet
371000
us-gaap Interest Paid Net
InterestPaidNet
410000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
39000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
423000
xlo Tenant Improvements Funded By Landlord
TenantImprovementsFundedByLandlord
2827000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
47000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
30000
CY2021Q3 us-gaap Restricted Cash
RestrictedCash
1553000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these condensed consolidated financial statements. Factors that may affect estimates, include expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Significant estimates of accounting reflected in these condensed consolidated financial statements include, but are not limited to, estimates related to accrued expenses, contingent liabilities associated with the consummation of specified transactions, including an initial public offering, the valuation of equity-based compensation, including incentive units, stock options and restricted common stock, and income taxes. Actual results could differ from those estimates.</p>
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
99767000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19238000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1551000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101320000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3400000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
825000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
450000
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1275000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9461000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8727000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2353000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1360000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7108000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7367000
us-gaap Depreciation
Depreciation
1000000.0
us-gaap Depreciation
Depreciation
700000
CY2021Q3 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
3238000
CY2020Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
11060000
CY2021Q3 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
3100000
CY2020Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
2013000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1569000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
287000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8194000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13732000
CY2021Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1600000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
133602056
CY2021Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
174808481
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
174808481
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
174783481
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
222888000
CY2021Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
225500000
CY2021Q3 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
18398248
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
133602056
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
66788528
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
78002000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
80250000
CY2020Q4 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
7030359
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220400000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
126000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Outstanding
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockOutstanding
18398248
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Outstanding
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockOutstanding
7030359
CY2021Q3 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2021Q3 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
3391136
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
810358
CY2021Q3 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
429109
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
151769
CY2021Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
22221124
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7995117
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
810358
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.51
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2993919
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.32
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8092
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
405049
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.17
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3391136
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M20D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15795000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
555282
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y7M17D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3243000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3391136
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
7.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M20D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
15795000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.16
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.60
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1091000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
683000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2887000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
930000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21927826
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8219575

Files In Submission

Name View Source Status
0001558370-21-016476-index-headers.html Edgar Link pending
0001558370-21-016476-index.html Edgar Link pending
0001558370-21-016476.txt Edgar Link pending
0001558370-21-016476-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20210930.xsd Edgar Link pending
xlo-20210930x10q.htm Edgar Link pending
xlo-20210930x10q_htm.xml Edgar Link completed
xlo-20210930xex31d1.htm Edgar Link pending
xlo-20210930xex31d2.htm Edgar Link pending
xlo-20210930xex32d1.htm Edgar Link pending
xlo-20210930_cal.xml Edgar Link unprocessable
xlo-20210930_def.xml Edgar Link unprocessable
xlo-20210930_lab.xml Edgar Link unprocessable
xlo-20210930_pre.xml Edgar Link unprocessable